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DOSIMETRI SINARAN TERHADAP PESAKIT YANG MENJALANI 
PEMERIKSAAN 18F-FDG PET-CT : SATU KAJIAN RETROSPEKTIF 
 
 
ABSTRAK 
 
Pesakit 18F-FDG PET-CT menerima dedahan radiasi daripada radiofarmaseutikal dan 
komponen CT. Objektif kajian ini adalah membuat penilaian dos sinaran pesakit dengan 
menggunakan kaedah pengiraan matematik dan pengukuran secara eksternal. Seramai 234 
orang dewasa menjalani imbasan PET-CT tunggal dan 83 orang daripadanya telah 
menjalani imbasan tambahan PET-CT pada hari yang sama. 25 pesakit kanak-kanak 
menjalani imbasan tunggal PET-CT. Penilaian dos organ adalah menggunakan aplikasi 
PMOD dan OLINDA/EXM untuk organ jantung, hati, buah pinggang dan pundi kencing. 
Keputusan masa diam organ hati adalah lebih lama diikuti organ lain seperti buah 
pinggang, pundi kencing dan jantung dengan masing-masing 0.593 j ± 0.055 j, 0.434 j ± 
0.031 j, 0.361 j ± 0.061 j and 0.326 j ± 0.024 j. Nilai purata dos organ terserap adalah 
0.028 mGy, 0.045 mGy, 0.084 mGy and 0.006 mGy bagi jantung, buah pinggang, hati 
dan pundi kencing. Penilaian dos efektif seluruh tubuh adalah berdasarkan garis panduan 
ICRP. Dos efektif seluruh tubuh untuk pesakit dewasa yang menjalani imbasan tunggal 
dan imbasan tambahan adalah 16.69 mSv ± 4.01 mSv dan 23.25 mSv ± 2.67 mSv. Dos 
efektif seluruh tubuh untuk pesakit kanak-kanak yang menjalani imbasan tunggal PET-CT 
adalah dalam julat 8.24 mSv ± 2.01 mSv to 14.23 mSv ± 2.67 mSv (dari peringkat umur 
0 sehingga 16 tahun). Keputusan pengukuran dos sinaran secara eksternal menggunakan 
meter tinjau pada jarak 1 meter dan pada permukaan seluruh tubuh adalah masing-masing 
106.09 μSvj-1 ± 40.33 μSvj-1 and 7.55 μSvj-1 ± 1.05 μSvj-1. Anggaran jumlah kumuhan 
(urin) adalah 31.47 MBq ± 19.89 MBq dalam tempoh masa 185.25 min ± 30.32 min 
sepanjang berada di premis PET-CT ini. Didapati keputusan dos organ terserap dan dos 
xiv 
  
 
efektif seluruh tubuh adalah relevan kerana pesakit adalah penghidap kanser. Dedahan dos 
radiasi pesakit yang dibenarkan pulang ke rumah adalah selamat kepada orang awam.  
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RADIATION DOSIMETRY OF PATIENTS UNDERGOING 18F-FDG PET-CT : A 
RETROSPECTIVE STUDY 
 
 
ABSTRACT 
 
18F-FDG PET-CT patients are exposed to radiation doses from 
radiopharmaceuticals and the CT component respectively. The objective of this study 
was to perform the patient dose assessment based on calculations and measurements. 
The collected data were of 234 adults who underwent single PET-CT exams while 83 
were those who underwent another sequential PET-CT examination on the same day 
of appointment at Institut Kanser Negara (IKN). 25 paediatrics underwent a single 
PET-CT examination. Organ dose assessment was performed using the PMOD and 
OLINDA/EXM software for heart, liver, kidney and urinary bladder. For adults the 
mean residence time result for liver is the longest, followed by kidney, urinary bladder 
and heart with mean average of 0.593 h ± 0.055 h, 0.434 h ± 0.031h, 0.361 h ± 0.061h 
and 0.326 h ± 0.024 h respectively. The mean result for organ absorbed dose of adult 
was 0.028 mGy, 0.045 mGy, 0.084 mGy and 0.006 mGy for heart, kidney, liver and 
bladder respectively. The whole-body PET-CT effective dose was determined from 
ICRP guidelines and the result of single and sequential PET-CT examination for adult 
was 16.69 mSv ± 4.01 mSv and 23.25 mSv ± 2.67 mSv respectively, while, paediatric 
patient ranged from 8.24 mSv ± 2.01 mSv to 14.23 mSv ± 2.67 mSv within the age 
from 0 to 16 years old. The patient mean dose rate reading at the surface and at 1 m 
before being discharged was 106.09 μSvhr-1 ± 40.33 μSvhr-1 and 7.55 μSvhr-1 ± 1.05 
μSvhr-1 respectively. The estimation of mean urine excretion was 31.47 MBq ± 19.89 
MBq within 185.25 min ± 30.32 min of spent time in this Centre. The result of this 
study for organ absorbed and whole-body PET-CT effective dose is relevant as the 
xvi 
  
 
selection of patient was suspected with metastasis disease and the patient discharged 
level from this Centre is safe for public.  
 
 1 
  
 
 
 
 
CHAPTER 1 
 
 
INTRODUCTION 
 
1.1 Background 
Positron Emission Tomography Computed Tomography (PET-CT) is a hybrid 
technology with a great combination of PET and CT scanners that gives metabolic or 
molecular information and cross-sectional information on anatomy respectively. PET-
CT has the ability to differentiate between benign or malignant tissue by localising the 
response of increased uptake of 2-[18F]Fluoro-2-deoxy-D-Glucose (18F-FDG) activity 
(Basu et al., 2011). With this such great capability in tumour determination, the system 
is more sensitive in quantitative and qualitative imaging that becomes a great choice 
to develop a rational treatment planning to the patient and  guide the clinician to decide 
for further therapy by either conforming response or signaling the need for a change 
in therapy (Boellaard, 2011).   
 
PET-CT scanner is widely used in diagnostic, staging and re-staging, monitoring 
response to therapy and detection of various types of early malignancies (Almuhaideb 
et al., 2011). It has been recognised to confirm the presence of tumour in the early 
stages (Boellaard et al., 2015). 
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Recently, there is a demand in using PET-CT with 18F-FDG in the clinical 
multidisciplinary field of nuclear medicine (Farwell et al., 2014). The awareness in 
dose minimisation demanding due to expanding record of patient listing which keep 
increasing. This Centre reported that the number of PET-CT examinations increased 
by more than100 cases per year which is over 500 cases in 5 years since 2010 to 2015. 
There was an increment of 20% paediatric cases since 2010 to 2015 (Kementerian 
Kesihatan Malaysia, 2016). 
 
PET-CT imaging is also referred to as molecular imaging. It uses radiopharmaceuticals 
such as 18F-FDG as a tracer in the field of nuclear medicine and is well established in 
imaging technique. The main role of the tracers is to identify the interaction of 
chemical and biological system that responded to molecular changes. In other words, 
radionuclides in diagnostic imaging and research purpose are widely use because of 
the advantage of bio-distribution information from the radiopharmaceutical.  
 
Patients who undergo PET-CT examination receive internal and external radiation 
dose exposures (Leide-Svegborn, 2010) originating from the administered 
radioactivity and CT component respectively. Generally in PET-CT, the radioactive 
tracer contributed more radiation dose to the patient rather than CT (Brix et al., 2005). 
This is because CT in PET-CT imaging uses the low dose CT compared to general CT 
which is specifically for diagnostic examinations (Zaidi, 2007). CT-based attenuation 
correction functions in PET-CT is able to reduce the emission imaging scan which 
these benefits most to the dose reduction with the aim to balance the examination 
benefits with the risk from radiation exposure. This cannot be obtained with a single 
scan of CT or PET alone (Cherry, 2009).  
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There is no dose limit to the patient in diagnostic and therapeutic procedures, but the 
urge of optimisation and radiation risk effect must balance the need. The possibility of 
having late radiation effects such as cancer became higher.  
 
Due to this concern, the International Atomic Energy Agency (IAEA) has provided 
guidelines to apply the radiation safety standards in nuclear medicine for protection 
against ionising radiation (Strzelczyk, 2006) which also comply with the Basic Safety 
Standard (BSS) needs. BSS (Strzelczyk, 2006) stated that the principle, justification, 
and optimisation of protection requirements in nuclear medicine or medical line are 
applied to medical exposure but not the dose limitation. In diagnostic medical 
exposure, the radiation dose level needs to be kept at a minimum level as the required 
diagnostic objective is achieved. To achieve this requirement, the radiation dose 
assessment to the patient is required to estimate the radiation dose to the whole-body 
as well as the critical organ. 
 
In clinical procedures, patient radiation dosimetry is important. Patients receiving 
radiopharmaceuticals via ingestion or injection are exposed to internal exposure. 
Definition of radiation dosimetry is dose assessment from the ionising radiation usage. 
The suggested estimation value to represent the amount of radiation exposure is, 
absorbed dose or effective dose. The absorbed dose is very important to determine how 
much radiation dose is received in the specific organ, while the effective dose is 
powerful in radiological protection for estimating the stochastic risk effect. The dose 
assessment can be done by performing calculations and external measurements. 
Calculations are nowadays simplified in softwares that apply the mathematical 
principles. While external measurements refer to the use of dosimeter or radiation 
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instrumentation. Patient specific dosimetry refers to individually and organ specific 
calculations. Every patient has different of biokinetic assessment, therefore the need 
of delivered correct radiation amount to the patient in diagnostic area estimate the 
potential radiation risk effects to the patient.   
 
Potential of patient benefit-risk due to the radiation exposure in both clinical and 
research application must be justified compared to associated risk (Strzelczyk, 2006). 
The potential radiation risk to the patient is non-stochastic (tissue reaction) and 
stochastic effect. The radiation risk of most concern is that due to the tissue reaction 
effect. Tissue reaction effect can be erythema, epilation, depression of bone marrow 
cell division, nausea, vomiting, diarrhea, central nervous system damage, fetal damage 
or death (Stabin (a)., 2008). Stochastic effect refers to the probability of having certain 
effects such as cancer and genetic effects. These are considered as late effects where, 
it may occur years or decades after the exposure.  
 
The basic fundamental in radiation dosimetry is based on the important information 
such as cumulative dose and residence time where these results led to organ absorbed 
dose in Gray units, however, other factor like organ weight also affect S-value in 
dosimetry. Besides that, the kinetic selection in dosimetry which gave the result of 
organ residence time which these also contribute the existence of ambiguity in the dose 
result as well.   
 
Guidelines in radiation dosimetry are provided by special task groups formed 
internationally like the International Commission on Radiological Protection (ICRP), 
the Medical Internal Radiation Dose (MIRD) committee and the Radiation Dose 
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Assessment Resource (RADAR) as they are concerned with radiation workers and 
patient dose exposure. They gathered all the information as for example in MIRD 
edition, they provided a radiation dosimetry handbook written from the beginning of 
data collection until the analysis of the results of patients that underwent nuclear 
medicine examinations. The progress in radiation dosimetry improved tremendously 
over the years. This task group invented mathematical modelling software such as 
Simulation De Dose (SIMDOSE), Medical Internal Radiation Dose (MIRDOSE) and 
Organ Level Internal Dosimetry Assessment/ Exponential Modelling 
(OLINDA/EXM) for patient dose calculation. This has been accepted worldwide 
(Stabin et al., 2012).  
  
The softwares are equipped with geometrical phantoms with different age, gender, and 
gestation period similar to the normal human anatomy. The phantoms were designed 
based on robust data collected under the IAEA internal dosimetry project. This tool 
was helpful and proven clinically reliable to the physicists and physicians (Stabin et 
al., 2005). Moreover, the upgraded version of the software has a flexible option to 
manipulate the organ weight to get dose results that mimic real patients and this is no 
doubt to be most suitable for specific patient dosimetry.  
1.2 Problem Statement 
From the literature review, the obtained result of whole-body PET-CT effective dose 
for adult and paediatric patients in this Centre was among the highest (Khamwan et 
al., 2010). This is based on a study done by Abdullah et al. (2014) and  Hussin et al., 
(2016) where during their data collection, the PET-CT scanner was not equipped with 
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Automatic Exposure Control (AEC) function and both studies were done at Hospital 
Putrajaya and Institut Kanser Negara respectively.  
Patients who underwent 18F-FDG PET-CT were exposed to high radiation doses in this 
Centre due to the following reasons : 
1)  Peadiatric patients were scanned using the whole-body adult protocol and they 
were exposed to high CT doses.  
2) Patients underwent another sequential PET-CT examination on the same day 
of appointment, which again means patients were exposed to unnecessary 
external exposure.  
3) Determination of patient doses was difficult due to the unique biokinetics. In 
previous practice, patient dose estimation was based on a reference source 
(dose calculation was based from average population), but, in this study patient 
specific dosimetry approach was used. This is important since specialists 
prescribe and give the exact dose to cure the illness and at the same time 
minimise the radiation health effects. This is in line with many studies done on 
patient dosimetry (Kolbert et al., 1997; Tsougos et al., 2010; Mattsson, 2015).  
4) In previous studies, the PET-CT scanner was not equipped with the AEC 
function.  This PET-CT scanner was in operation until April, 2015. The AEC 
function is a dosimetry tool and it is used to optimise radiation exposure based 
on tissue density while maintaining the image quality.  
 
Later in May 2015, the PET-CT scanner in this Centre was installed with Automatic 
Exposure Control (AEC) function. Therefore, a comparison on dose reduction 
effectiveness with the use of AEC function was evaluated based on data collection 
before and after installation.  
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1.3 Objective of Study 
The main objective of this study was to evaluate radiation dose received by the patients 
underwent 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed 
Tomography (PET-CT) examinations in nuclear medicine department, Institut Kanser 
Negara (IKN), Putrajaya by performing radiation dosimetry by calculations and by 
measurements. 
 
The specific objectives are as follows:  
A. Dosimetry by calculation : 
a) to estimate the organ absorbed dose from obtained results of residence 
time of the selected organs and patients using OLINDA/EXM software. 
b) to calculate the whole-body PET-CT effective dose of the adult and 
paediatric patients based on ICRP guidelines. 
 
B. Dosimetry by measurement :  
a) to collect the radiation dose exposure of patients underwent 18F-FDG 
using calibrated survey meter before discharged from this Centre at 1 
metre distance and at surface of trunk area.  
 
1.4 Scope of Study 
This is a retrospective study that covers patient specific dosimetry and radiation risk 
estimation based on the results of internal and external dosimetry. This study focused 
on assessment of organ absorbed dose, whole-body effective dose and dose rate 
exposure of the patient. The organ absorbed dose was estimated using OLINDA/EXM 
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software while whole-body PET-CT effective dose determination was performed as 
recommended by ICRP.  
 
The selection of patients was done by nuclear medicine specialists and physicists at 
IKN centre. 80% was covered in patient dosimetry, while another 20% in PET-CT 
imaging. This retrospective study was under ethics approval obtained from Ministry 
Of Health (MOH-NMRR) and Jawatankuasa Etika Penyelidikan (Manusia) of USM 
(JEPeM). 
 
The tools for imaging and dosimetry calculation such as PMOD and OLINDA/EXM 
software was used in this study. No biological sample involved in this work. The 
dosimetry calculation was performed on data retrieved with the permission from 
nuclear medicine department, IKN. There was no physical contact with patients and 
no volunteer participant was involved in this study.  
 
1.5  Thesis organisation 
This thesis consists of five chapters.  
 
Chapter 1 presents an introduction to the thesis. It also discusses the importance of 
radiation dosimetry assessment in clinical applications because of the high demand of 
diagnostic nuclear medicine. The importance of having patient dose evaluation is to 
acknowledge the radiation risk associated with these procedures. This Chapter also 
presents the problem statement, objectives and scope of the study. 
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Chapter 2 discusses the history and development of nuclear medicine dosimetry. The 
function of radionuclide and radiopharmaceuticals as tracer in nuclear medicine is 
important in order to obtain good images on the behaviour of the disease. In radiation 
dosimetry, the description of phantom, method of calculation and uncertainties is 
explained in this Chapter. The radiological risk issue such as biological effects which 
refer to deterministic or stochastic effects are also included whereby the evaluation of 
the patient risk-benefit is an important consideration in nuclear medicine dosimetry.  
 
Chapter 3 discusses materials and methodology involved in this study. The data 
collection is explained in this Chapter. The dosimetry calculation and the use of 
suitable statistic such as SPSS in data analysis is also presented. The use of 
mathematical softwares Periphery MODule (PMOD) and Organ INternal Dose 
Assessment/ EXponential Modelling (OLINDA/EXM) as an internal dosimetry tool 
in this study and the statistical analysis is also discussed in this Chapter. 
 
Chapter 4 presents results and discussions of this study. The main result of this study 
is divided into two (2) sections where part one (1) covers dosimetry by calculation 
which focused on absorbed dose and whole-body PET-CT effective dose while part 
two (2) covers dosimetry by measurement which referred to external measurement 
using the OSL and survey meter. The radiation dosimetry was based from ICRP and 
RADAR perspective. The obtained result also attached with dedicated graphs and 
tables to ensure well explanation in the discussion section.  
 
Chapter 5 presents the conclusions, limitation of study and recommendations for future 
works.  
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CHAPTER 2 
 
 
THEORY AND LITERATURE REVIEW 
 
2.1 Discovery of Radiation 
In 1895, Wilhelm Conrad Roentgen discovered a kind of invisible light and 
subsequently named it as X-rays. A year later in 1896, Sir Henri Becquerel found 
similar lights from uranium salts and named it as radioactive when he noticed this 
element continue transmitting by itself after many experiments. Marie Curie, who was 
a student of Sir Henri Becquerel became interested in this discovery and carried out 
further experiments where she later discovered other radioactive elements such as 
Polonium, Radium and Thorium. The discovery of X-rays initiated the idea for the 
medical world to use it for the observation of the internal structure of internal organs 
(Frame, 2004). Since its discovery, people were overly obsessed with radiation. In 
1924, the approach of radioactive material as a radiotracer was first carried out in 
animals using Plumbum-210 and Bismuth-210. With the high confidence level, the 
Bismuth 214 was then used to evaluate blood flow rates in humans a year later (Reed, 
2011). Since then, many more radiotracers such as Iodine-131, Cobalt-60, 
Technetium-99 and others have been discovered. Thus, this signalled the beginning of 
nuclear medicine era.  
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Although the discovery of radioactive elements provided the medical world  with a 
new approach in many aspects, however, the radiation side effects resulting from the 
uncontrolled use has led to adverse effects. Industrial workers such as radium dial 
painters, were found to be suffering from bone cancer due to the accumulation of 
radiation exposure. Moreover, a number of workers in the medical line who were 
actively involved in X-ray work have been shown to suffer from leukemia and 
pernicious anaemia (Finch, 2007). Due to these incidences, the awareness towards 
radiation exposure from the use of radioactive materials have risen and affected the 
industry and healthcare.  
 
2.2 Nuclear Medicine Introduction 
Knowledge in healthcare growing up very fast, especially matters related to radiation. 
With the introduction of radiotracers, with the interest to study the internal structure 
has led to radiology, radiotheraphy and nuclear medicine. Nuclear medicine is one of 
medical branches which use a small amount of radioactive tracer to detect disease 
either for diagnostic or therapeutic purposes (Fahey, 2016). The radioactive tracer is a 
combination of radioisotope and pharmaceutical (drugs) that will be administered to 
the patient via injection, ingestion or inhalation. The radioactive tracer will enter the 
bloodstream and ends up to the problematic area and this can be detected when patient 
undergoes the imaging scan. The problematic area was visualised in nuclear medicine 
imaging tools when there was high uptake in the internal organs. Depending on the 
behaviour of the selected radiotracer, nuclear medicine imaging provides the 
information about the anatomy and physiology of the disease. Each radiotracer has its 
own targeted area. They will stay in the organ at certain time until it decayed physically 
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and biologically (Balasubramanian, 2016). Normally, only radioactive (radiotracer) 
with short half-life is used in nuclear medicine. This is very unique compared to other 
medical discipline. The most common radioisotopes used in nuclear medicine field for 
either diagnostic or therapeutic are Technecium-99, Iodine-125, Flourine-18, Iodine-
124, Yttrium-90, and Iodine-131 (Saha, 2010).  
 
The radiotracer was detected based on the (radiation) energy that emitted from the 
patient’s body to the detector via collimator. The data was then transferred into 
electrical signal and visualised in image form. These images formed can be read by 
the physician based on the uptake distribution in internal organ of the patient. Nuclear 
medicine imaging has been proven as a great tool in the diagnostic and therapeutic of 
disease detection like tumour localization, kidney function, lung prefusion and thyroid. 
No surgical or biopsy was needed to gain the information on disease characteristic 
which makes nuclear medicine services safe and considered as one of the best 
alternative in medical lines.  
 
2.2.1 Radionuclide and Radiopharmaceutical Production 
Radiopharmaceutical 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) is a combination 
of radioisotope18F and pharmaceutical drugs, FDG and is known as PET 
radiopharmaceutical (Wadsak & Mitterhauser, 2010). This is due to the nature of 18F-
FDG decay by emitting positron and most of the positron emitters have a short half-
life like 18F with 109.74 minutes.  
 
Radioisotope 18F is produced in a cyclotron. Cyclotron is a particle accelerator which 
accelerates protons in a spiral path (IAEA, 2012). The nuclear reaction can be 
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simplified as 18O(p,n)18F. Accelerated high energy protons (H+) entered the nucleus of 
high pressure enriched water of 18O atom (target medium), and transformed it into 
radioisotopes 18F by discharging a neutron (Strijckmans, 2001).  
 
18F-FDG can be used as a glucose-analogue and is the most current used tracer due to 
its versatility in glucose interaction detection (Fletcher et al., 2008; Cho et al., 2011). 
Tumour cell is categorized as an active cell which has high mitotic rate development. 
FDG accumulation is proportional to glucose utilisation. It responds to the 
consumption of glucose in cells as well as with hexokinase activity (R Boellaard et al., 
2015). During normal glycolysis process, the glucose molecule is phosphorylated by 
hexokinase and undergoes a number of further enzymatic reactions for energy 
production. But when using the FDG, after the phosphorylation phase, it cannot  
proceed with further glycolysis process because of the different end form of glucose 
and will end up trapped in the cells until physical decay process occurs (Perng et al., 
2015). Therefore, FDG PET has proven to be a sensitive imaging modality in 
differentiating between benign and malignant tissue (Damian et al., 2013). 
 
Brain, kidney, urinary bladder and heart are the major organs in human. Data from 
previous study have shown that almost 15 - 20 % of the injected 18F was eliminated by 
renal system or by pharmaco-kinetically within 16 minutes after receiving the 
injection, and 75 % were remained in the cells for physical decay (Staaf et al., 2012).   
 
In the renal system pathway, the kidney is directly involved with other excretion organ 
such as urinary bladder. Is has been shown that due to the rapid elimination by renal 
system, this system contains high uptake of 18F in the first hour. In normal patients, 
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low concentration of 18F retains in the kidney and not enter the urinary bladder, so the 
patient will stay radioactive for some-while (Minamimoto et al., 2007). 
 
Moreover, FDG PET has also been proven to be capable of detecting attenuation of 
cognitive in alzheimer disease and mild cognitive impairment based on measurement 
of glucose metabolism (Nobili & Morbelli, 2010; Cohen & Klunk, 2014). 
 
2.2.2  Positron Emission Tomography-Computed Tomography (PET-CT)   
          Hybrid Modality 
Gamma camera is the main imaging tool in nuclear medicine procedures. What makes 
it different with other imaging scans is that it uses different scan techniques such as 
SPECT-CT and PET-CT. SPECT-CT system detects single photon while PET-CT 
detects dual positron energies that emits from the patient’s body. This study involves 
only the PET-CT application.  
 
2.2.2(a) Introduction 
The detection of annihilation photons from positron emission decay process is the main 
element in PET-CT imaging technique (Sandip Basu et al., 2011). 18F is an unstable 
atom due to having excess of protons in its atom. A proton in a nucleus of an atom is 
converted into a neutron and a positron. The positron is ejected together with neutrino.   
 
Tissue cells are enriched with electrons. When positrons enter the tissue cell, it will 
have short lifetime and will quickly lose its kinetic energy during its travelling phase. 
Once the energy almost at rest momentum, it collides with other electron in the cells 
and become positronium (combination of positron and electron) about 10-10 s.  After 
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that event, the annihilation process will take place (Sandip Basu et al., 2014). During 
the annihilation process, the energy of 1.022 MeV is released. This is based on 
Einstein’s mass energy formula as:  
 
E=mc2           (Eq. 2.1) 
 
where; 
E is energy  
m is mass 
c is speed of light in vacuum 
 
Two high energy photons emitted in opposite direction (180°) with energies of 511 
keV are produced. These high kinetic energy photons have the ability to penetrate the 
body and hit the rings of the detector (crystal).    
 
This interaction provides the detector with the signal and reacts by emitting visible 
light (scintillation light), and this is subsequently detected by photomultiplier tubes 
(PMT) and converted into an electrical current. The data are then collected and 
recorded as an acquisition data. Finally, the data is reconstructed (Phelps et al., 2006; 
Sandip Basu et al., 2014). 
 
2.2.2(b) Principle of PET-CT Imaging 
Acquisition data are collected from the coincidence events (referred to detected 
annihilation process). Only true coincidence events would be recorded where two 
detected annihilation photons of 180° apart originating from the same radioactive 
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decay and they interacted along the Line Of Response (LOR) (Fahey, 2002). But 
somehow other events like random and scattered events are also detectable by the 
detector and this needs to be first corrected to get the close image to radioactivity 
concentration (Kapoor et al., 2004).  
 
The data are collected in different angles and radius of detector to complete the cross 
sectional of the images which refer to trans-axial and axial. The acquisition mode can 
be in two dimensional (2D) or in 3 dimensional (3D). 2D mode refers to the direct 
planes where recorded coincidence was within the LOR of the detector ring and 3D 
mode refers to the cross planes with an average amount of coincidence between few 
ring detectors. This will provide correct information of location and annihilation time 
(Fahey, 2002).   
 
For 3D mode, data is collected in oblique LOR and it is more sensitive than the 2D 
acquisition (Lodge et al., 2006). The advantages of using 3D mode include minimising 
the patient scan time and reducing the amount of radioactivity injection (Nogueira et 
al., 2015).    
 
Attenuation correction is referring to acquisition data that has been corrected. Software 
will remove the unwanted signal or noise such as from random and scattered events. 
This aims to obtain the result of tissue activity concentration value that represents the 
image volume. Attenuation correction can be performed either with direct 
measurement or calculation (Parker, 2005). Direct measurement refers to transmission 
scan and blank scan while calculations were based from assumption made on amount 
of attenuation from source outside will reflect the amount of attenuation inside with 
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constant attenuation correction, μ. Direct measurement is more accurate compared to 
the calculated method (Boellaard et al., 2015). In PET-CT studies, attenuation 
correction and scatter correction are performed using combination of CT transmission 
data and calculation method (Boellaard, 2009). 
 
The scan images of the annihilation photon which detected and recorded in the raw 
data of PET will be reconstructed using the mathematical algorithms of computed 
tomography. The reconstruction method is important to convert the raw data which 
consist of the information on location of the annihilation takes place in the 2D or 3D 
images. These can be quantitatively detected reflecting the distribution of positron 
emitting radiopharmaceuticals in the scan object. 
 
There are two main reconstruction methods used which are analytical or iterative, 
which referring to the filtered back-projection (FBP) or Ordered Subset Expectation 
Maximisation (OSEM), respectively (Sandip Basu et al., 2011). Filtered back-
projection (FBP) uses the analytical method where it relates the lines integral 
measurement to the activity distribution in the object.  As for the iterative method, it 
involves the statistical approach, and is known to be more quantitatively accurate than 
the analytical method. In the reconstruction techniques, multiple iteration steps were 
used to get a better reconstruction result which could indirectly minimise the artefact 
effect to the image. The image is then directly calculated in a single reconstruction 
step, so this makes the iterative method better compared to the FBP (A. Alessio & 
Kinahan, 2006). 
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The image can be displayed in Medical Interface Programme (MIP) and it is 
constructed in a 3D image view in trans-axial, coronal and sagittal planes. The CT 
images presented within grey and white area where it is based on tissue density (Cho 
et al., 2011). PET images is visualised in pseudo colour coding, where it guides the 
user to identify a particular activity concentration with different level of pseudo colour. 
Positron Emission Tomography is a great technique compared to Single Photon 
Emission to define each of the volume of element referred to concentration of 
radioactive tissue (Welch et al., 2013). 
 
2.2.2(c) Standard Clinical Procedure of PET-CT Imaging  
 Clinical procedure begins with the patient preparation, followed by the procedure of 
scan until the patient is discharged. During patient preparation, the patient is 
counselled on diet one week prior to the date of appointment. Patient is advised to start 
fasting at least 4-6 hours before scan. However, they are allowed to drink only plain 
water and take their normal medicine. On the day of appointment, they must inform 
the staffs if they are likely to be pregnant, breastfeed, have drug allergy, claustrophobic 
and diabetes mellitus. Once they have passed the physical fitness examination, they 
are eligible to receive an injection of radiopharmaceutical and proceed with the PET-
CT examination.  
 
Small quantity of radioactive tracer 18F-FDG will be injected into the vein of their hand 
or elbow. The dose was given based on body weight of 5 MBq kg-1. There is no 
significant side effect as a result of this injection. After receiving an intravenous (IV) 
injection, patient needs to rest in the provided room approximately for 1 h (60 min). It 
is important that no physical activities such as unnecessary talking, chewing, eating or 
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any muscular or strenuous exercise as this may affect the result of the scan.  Patient 
were asked to void the urine before proceed for PET-CT scan. This is important to 
minimise the scattered phenomenon in the body which can affect the image result i.e 
artefact images.  
 
PET-CT scan procedure starts with a CT scan for two seconds which emits X-rays 
radiation followed by PET scan for approximately 20 to 30 min.  It emits the gamma 
radiation which origin from positron annihilation process in the human body after 
injecting the radiopharmaceutical 18F-FDG into the body before. The CT scan starts 
with a CT scout followed by CT helical for few seconds. The setting parameters for 
CT scout scan and CT helical scan are at voltage of 120 kVp, 100 mAs current, pitch 
at 0.8 and voltage of 140 kVp, current range of 10-100 mAs, pitch at 1.35, respectively 
as a standard clinical protocol for adult patient. Slightly different parameters are 
applied for the paediatric use. This machine is equipped with Automatic Exposure 
Control (AEC) function where the current and voltage was adjusted automatically 
based on tissue density.  
 
2.2.2(d) Radiation Exposure Aspect In PET-CT  
Patient underwent PET-CT imaging is exposed to dual radiation from the 
radiopharmaceutical 18F-FDG (internal radiation) and the CT component that 
generates the X-rays radiation (external radiation). The CT effective dose depends on 
the applications, protocols and CT systems (Boellaard et al., 2015), while PET 
effective dose depends on radiopharmaceuticals, administered activity and weight of 
the patient (Gelfand, 2009). The risk of radiation exposure also depends on the 
patient’s age. For instance, based on previous studies, children have been shown to be 
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more sensitive to radiation compared to adult (Kollek & Karwowska, 2009; Figueira 
et al., 2015).  
 
However, radiation exposure can be reduced by adjusting the acquisition setting 
parameters such as tube current, tube voltage, filter, sinogram smoothing and clipping 
(Xia, 2012), crystal detector, setting of Full Width Half Maximum (FWHM) (Basu et 
al., 2011), as well as the reconstruction parameter (Vriens et al., 2010). Reconstruction 
settings (analytical versus iterative reconstruction, post-reconstruction filtering and 
image matrix size) could potentially influencing the quantification due to the effect of 
artefacts, noise levels and lesion size dependency (Vriens et al., 2010). 
 
Besides that, they are also other factors that could  contribute to patient dose reduction 
such as fasting blood glucose level, FDG uptake period, FDG distribution and 
clearance, patient motion (breathing) and patient discomfort (stress), which are all 
could influence the quantification, metal artifacs, glucose metabolism, and influence 
of attenuation correction (Vriens et al., 2010). Patient are recommended for pre-
hydration plan to optimize the distribution of FDG throughout the body. This is 
important especially when involve a study on kidney and pelvic area (Lubberink et al., 
2004; Coenen et al., 2010).  
 
Automatic Exposure Control (AEC) technique is an alternative way to optimise the 
radiation dose exposure to the patient by giving the minimum CT dose to the patient 
(Mulkens et al., 2005). This technique applies the modification of CT tube current 
based on x,y and z planes according to the size and attenuation of the scanned body 
(McCollough et al., 2013). Greess et al., 2002 found that the CT exposure dose can be 
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reduced to 50% with the application of this technique, but the possibilities for heavy 
patient to receive higher exposure dose is there because the tube current needs to be 
increased to maintain the constant image noise.  
 
2.3 Nuclear Medicine Dosimetry  
Dosimetry or dose assessment is the calculation of the amount of deposited energy 
absorbed in tissue or organ that correlates with the radiation risk effect. This is 
important in order to evaluate radiation risk over benefits to the patient. Dose 
assessment in diagnostic is estimation using collective sample of population 
coefficient in calculation, while in therapeutic, the calculation is based on individual 
patient specific biokinetic. Dosimetry by calculation usually based on Monte Carlo 
simulation from developed phantom which already formed into computational 
software. While, dosimetry by measurement, which also known as external exposure 
where the assessment of dose based from the emitted radiation source outside the 
human body. However, people may have different views on dosimetry calculations 
due to some uncertainties factors.  
 
Established organisations such as International Commission on Radiological 
Protection (ICRP), Medical Internal Radiation Dose (MIRD) and Radiation Dose 
Assessment Resource (RADAR) have established the fundamental concept in 
dosimetry such as quantities and units, equations, methods or techniques. All these 
efforts help to standardise the dosimetry result.   
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2.3.1 Quantities and Units 
The International Commission on Radiation Units and Measurements (ICRU) has 
introduced the quantity measurement in radiation field that aim to assess the biological 
effects resulting from external and internal exposure to ionising radiation in terms of 
stochastic (cancer induction, genetic effects) as well as deterministic effects (tissue 
effects) in order to have sufficient mechanisms to control these effects.  
 
2.3.1(a) Absorbed Dose, D 
Absorbed dose is defined as a measurement on the amount of radiation energy 
absorbed in a target tissue per unit mass. The System International (S.I) unit is in Gray 
(Gy) where,  
1 Gy = 1 J kg-1 
1 Gy = 100 rad 
 
          D = 
dℇ
d𝑚
 = 1 Gy                                  (Eq. 2.2) 
 
In internal dosimetry calculation system, we assume the tissue has uniform distribution 
of radioactive material using a generic Equation 2.3: 
      
 
          
Where,  
D is absorbed dose (rad or Gy) 
Ã is cumulated activity (mCi-hr or MBq-sec) 
ni is number of radiations with energy,E emitted per nuclear transition 
m
 E n  A k
 = D
iii
i

~
(Eq. 2.3) 
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Ei is energy per radiation (MeV) 
øi is fraction of energy absorbed in the target 
m is mass of target region (g or kg) 
k is proportionality constant (rad-g/mCi-hr-MeV or Gy-kg/MBq-sec-MeV) 
 
With S value formula : 
 
    
  (Eq. 2.4) 
 
MIRD has simplified the Equation 2.3 and 2.4: 
 
D = Ã.S                                                   (Eq. 2.5) 
 
where: 
Ã is the cumulated activity in source organ  
S is S value derived from an appropriate phantom and Monte Carlo simulation 
 
Absorbed fraction  is fraction of radiation energy absorbed in a target organ per 
radiation energy emitted in the source organ. The value for absorb fraction is between 
0.01.0. Source organs have concentrations larger than the average body 
concentration depending on the source and target geometry (Monte Carlo method). In 
theory, the absorbed dose is dependents on the fraction of the administered activity in 
organ and rate of elimination from source organ. 
 
m
  E n  k
 = S
iii
i

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Furthermore, there were authors or groups that have interest in developing the generic 
absorbed dose equation to another form. MIRD organisational use above Equation (2.4 
and 2.5) in their calculation. While RADAR has modified the equation to be simpler 
in Equation 2.6: 
 
D = N x DF                                     (Eq. 2.6) 
Where,   
N is number of disintegrations in the source 
DF is dose factor 
 
 
              (Eq. 2.7) 
 
 
Where,  
WR is radiation weighting factor 
 
The DF is written with the function of WR which includes the use of a radiation-
weighting factor, as defined by the International Commission on Radiological 
Protection (ICRP) (ICRP, 1991; Thorne, 1992). Fundamentally, the expression of S-
value and Dose Factor (DF) are similar (Stabin et al., 2005).  
 
2.3.1(b) Equivalent Dose, HT 
Equivalent dose is multiplied the absorbed dose with the radiation weighting factor, 
WR to reflect the biological effect. Which has a relationship with the LET of different 
m 
 WR  E  n   k 
 = DF 
i i i 
i 
  
WR 
 25 
  
 
types of radiation. The equivalent dose is used for radiological protection and suitable 
only for human estimation. The S.I unit is in Sievert (Sv).  
1 Sv = 100 rem. 
HT = D.WR                                                (Eq. 2.8) 
  
Where,  
HT is equivalent dose 
D is absorbed dose 
WR is radiation weighting factor 
 
2.3.1(c) Effective Dose, ED 
Effective Dose is the product of equivalent dose weighted, HT and tissue weighting 
factor, WT. The tissue weighting factor reflects the risk or tissue harmless, while 
equivalent dose weighted for an organ or tissue is the proportion of the risk of 
stochastic effects to the total risk of stochastic effects when the whole body is 
irradiated uniformly. The examples of stochastic effects are cancer risk, life shortening 
and hereditary effects. The S.I unit is in Sievert (Sv).   
1 Sv = 100 rem 
ED = ΣΤΗΤ.WT                                                  (Eq. 2.9) 
where, 
ED is effective dose 
HT is weighted equivalent dose 
WT is organ weighting factor which is ΣΤ WT = 1.0 in case of X-rays and Gamma- 
rays        
